These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20946279)

  • 1. Effect of substance abuse on defibrillation threshold in patients with implantable cardioverter-defibrillator.
    Perrine SA; Nayak R; Bharadwaj AS; McKelvey G; Mohamad T; Jacob S
    Pacing Clin Electrophysiol; 2011 Feb; 34(2):193-9. PubMed ID: 20946279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of defibrillation threshold testing-induced ventricular fibrillation on renal function.
    Shin JH; Khunnawat C; Baez-Escudero J; Knight BP; Beshai JF
    J Interv Card Electrophysiol; 2013 Dec; 38(3):209-15. PubMed ID: 24113852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of defibrillation efficacy using implantable cardioverter-defibrillator with single- or dual-coil defibrillation leads and active can.
    Lubiński A; Lewicka-Nowak E; Zienciuk A; Królak T; Kempa M; Pazdyga A; Raczak G; Swiatecka G
    Kardiol Pol; 2005 Sep; 63(3):234-41; discussion 242-3. PubMed ID: 16180177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of high defibrillation threshold in the modern era.
    Lin EF; Dalal D; Cheng A; Marine JE; Nazarian S; Sinha S; Spragg DD; Tandri H; Halperin H; Calkins H; Berger RD; Tomaselli GF; Henrikson CA
    Pacing Clin Electrophysiol; 2013 Feb; 36(2):231-7. PubMed ID: 23121046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry.
    Arnson Y; Suleiman M; Glikson M; Sela R; Geist M; Amit G; Schliamser JE; Goldenberg I; Ben-Zvi S; Orvin K; Rosenheck S; Adam Freedberg N; Strasberg B; Haim M
    Heart Rhythm; 2014 May; 11(5):814-21. PubMed ID: 24486799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention implantation of cardioverter defibrillator without defibrillation threshold testing: 2-year follow-up.
    Bianchi S; Ricci RP; Biscione F; Sgreccia F; Di Belardino N; Rossi P; Giuli S; Grammatico A; De Santo T; Santi E; Merico M; Piccirillo G; Azzolini P; Santini M; Puglisi A
    Pacing Clin Electrophysiol; 2009 May; 32(5):573-8. PubMed ID: 19422577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantable cardioverter defibrillator with and without defibrillation threshold testing.
    Codner P; Nevzorov R; Kusniec J; Haim M; Zabarski R; Strasberg B
    Isr Med Assoc J; 2012 Jun; 14(6):343-6. PubMed ID: 22891393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Semprini L; Palano F; Santini D; Musumeci B; Santolamazza C; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2017 Jan; 28(1):103-108. PubMed ID: 27862589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reproducibility of the effectiveness of defibrillation for terminating induced ventricular fibrillation using intraoperatively measured defibrillation threshold energy in patients with implanted cardioverter-defibrillator].
    Jung J; Neuzner J; Himmrich E; Vester E; Michel U; Fries R; Pitschner H; Liebrich A; Ganschow U; Heisel A
    Z Kardiol; 1998 Dec; 87(12):971-7. PubMed ID: 10025070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Efficacy and Necessity of Routine Defibrillation Threshold Testing in Patients Undergoing Implantable Cardioverter-Defibrillator (ICD) Implantation.
    Ashino S; Nakai T; Sonoda K; Sasaki N; Kurokawa S; Ikeya Y; Okumura Y; Ohkubo K; Kunimoto S; Watanabe I; Hirayama A
    Int Heart J; 2015; 56(6):618-21. PubMed ID: 26549282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mobile telephones on the function of implantable cardioverter defibrillators.
    Tandogan I; Ozin B; Bozbas H; Turhan S; Ozdemir R; Yetkin E; Topal E
    Ann Noninvasive Electrocardiol; 2005 Oct; 10(4):409-13. PubMed ID: 16255750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is the determination of the defibrillation threshold in patients with an implantable cardioverter-defibrillator still required?].
    Licka M; Jahn L; Kelemen K; Voss F; Trappe K; Becker R; Bikou O; Hauck M; Koch M; Katus HA; Bauer A
    Herzschrittmacherther Elektrophysiol; 2011 Dec; 22(4):209-13. PubMed ID: 22080419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion?
    Russo AM; Sauer W; Gerstenfeld EP; Hsia HH; Lin D; Cooper JM; Dixit S; Verdino RJ; Nayak HM; Callans DJ; Patel V; Marchlinski FE
    Heart Rhythm; 2005 May; 2(5):456-61. PubMed ID: 15840466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Blatt JA; Poole JE; Johnson GW; Callans DJ; Raitt MH; Reddy RK; Marchlinski FE; Yee R; Guarnieri T; Talajic M; Wilber DJ; Anderson J; Chung K; Wong WS; Mark DB; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2008 Aug; 52(7):551-6. PubMed ID: 18687249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of very high defibrillation thresholds (DFT) and efficacy of subcutaneous (SQ) array insertion during implantable cardioverter defibrillator (ICD) implantation.
    Verma A; Kaplan AJ; Sarak B; Oosthuizen R; Beardsall M; Higgenbottam J; Wulffhart Z; Khaykin Y
    J Interv Card Electrophysiol; 2010 Nov; 29(2):127-33. PubMed ID: 20865309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estimation of defibrillation threshold using abdominally implanted cardioverter-defibrillator with an additional defibrillation pole in a dual-coil lead endocardial defibrillation system].
    Pazdyga A; Lubiński A; Lewicka-Nowak E; Królak T; Kempa M; Zienciuk A; Raczak G
    Pol Merkur Lekarski; 2007 Feb; 22(128):86-9. PubMed ID: 17598649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful implantation of cardiac defibrillators without induction of ventricular fibrillation using upper limit of vulnerability testing.
    Green UB; Garg A; Al-Kandari F; Ungab G; Tone L; Feld GK
    J Interv Card Electrophysiol; 2003 Feb; 8(1):71-5. PubMed ID: 12652181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable transvenous cardioverter-defibrillators.
    Bardy GH; Hofer B; Johnson G; Kudenchuk PJ; Poole JE; Dolack GL; Gleva M; Mitchell R; Kelso D
    Circulation; 1993 Apr; 87(4):1152-68. PubMed ID: 8462144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.